1. How would you describe the pharmaceutical industry’s strategy leading up to the opioid crisis? Is it ethical? Why or why not?

2. Is there anything that the pharmaceutical industry has done or is now doing in the aftermath of that crisis that could legitimately be considered as “unethical” by its stakeholders? What grade would you assign to the industry for its handling of the crisis? Explain.

3. In what ways, if any, should the stakeholders in the U.S. opioid crisis bear responsibility? Are there any changes to the industry actors’ CSR strategy that you would suggest?

4. If some shareholders complained that the pharmaceutical industry has been spending too little or too much effort on corporate social responsibility, what would you tell them?

5. Is the pharmaceutical industry striving to conduct business in a socially responsible manner? What specific additional actions could the pharmaceutical industry take that would make an even greater contribution to CSR? What might be the long-term interests of shareholders? How might a commitment to CSR contribute to the pharmaceutical industry’s competitive advantage or profitability?

Must include 3 additional resources to support your responses!!